SIGN 140: Management of primary cutaneous squamous cell carcinoma

Zusammenfassung

SIGN 140 • Management of primary cutaneous squamous cell carcinoma A national clinical guideline June 2014 Evidence Help us to improve SIGN guidelines - click here to complete our survey KEY TO EVIDENCE STATEMENTS AND RECOMMENDATIONS LEVELS OF EVIDENCE 1 ++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well conducted meta-analyses, systematic reviews, o

Kerninformationen

GOOD PRACTICE POINTS  Recommended best practice based on the clinical experience of the guideline development group NHS Evidence has accredited the process used by Scottish Intercollegiate Guidelines Network to produce guidelines. Accreditation is applicable to guidance produced using the proce...

Management of primary cutaneous squamous cell carcinoma. Edinburgh: SIGN; 2014. (SIGN publication no. 140). [June 2014]. Available from URL: http://www.sign.ac.uk SIGN consents to the photocopying of this guideline for the purpose of implementation in NHSScotland . Management of primary cutaneous ...

It has a variable spectrum of clinical presentation and risk, ranging from the common, usually low-risk, keratotic plaque through to the less common, larger, rapidly growing and usually high-risk, exophytic skin lesion nodule. 1, 2 Squamous cell carcinoma is the second most common skin cancer, a...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen